4,837 Gilead Sciences, Inc. $GILD Shares Acquired by Summit Global Investments

Posted by George Bondi on Nov 1st, 2026

Gilead Sciences logo Summit Global Investments lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 41.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 16,549 shares of the biopharmaceutical company’s stock after acquiring an additional 4,837 shares during the period. Summit Global Investments’ holdings in Gilead Sciences were worth $2,467,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. MGO One Seven LLC raised its holdings in shares of Gilead Sciences by 31.0% in the third quarter. MGO One Seven LLC now owns 17,858 shares of the biopharmaceutical company’s stock worth $2,662,000 after buying an additional 4,231 shares during the last quarter. Americana Partners LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at about $369,000. Aprio Wealth Management LLC lifted its holdings in Gilead Sciences by 11.0% in the third quarter. Aprio Wealth Management LLC now owns 17,212 shares of the biopharmaceutical company’s stock valued at $2,565,000 after acquiring an additional 1,712 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Gilead Sciences by 2,702.7% in the 3rd quarter. International Assets Investment Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $37,262,000 after purchasing an additional 241,080 shares during the period. Finally, Canopy Partners LLC boosted its stake in shares of Gilead Sciences by 5.8% during the 3rd quarter. Canopy Partners LLC now owns 3,579 shares of the biopharmaceutical company’s stock worth $533,000 after acquiring an additional 197 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 3.1%

Shares of GILD opened at $170.68 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $175.65. The stock has a market capitalization of $211.63 billion, a PE ratio of -54.01 and a beta of 0.31. The company’s 50-day simple moving average is $150.87 and its 200-day simple moving average is $139.79.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the previous year, the firm posted $2.47 earnings per share. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the insider owned 113,684 shares in the company, valued at approximately $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. Cantor Fitzgerald increased their target price on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup increased their price objective on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday. Bank of America increased their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. TD Cowen lifted their price target on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a report on Friday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $169.19.

Read Our Latest Stock Analysis on GILD

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.